Enhanced MR imaging versus CT in assessment of disappearing colorectal metastases.
Enhanced MR imaging is superior to contrast-enhanced CT imaging for assessment of disappearing colorectal liver metastases (CRLMs) after chemotherapy, according to a study published in Radiology.
Researchers from Korea performed a retrospective study to compare the diagnostic performances of contrast–enhanced CT and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid–enhanced liver MR imaging (EOB MR imaging) in the evaluation of disappearing colorectal liver metastases CRLMs.
The researchers used data from eight hospitals. Eighty-seven patients with 393 CRLMs, each patient with one or more CRLMs that later disappeared on contrast-enhanced CT scans after chemotherapy, and subsequently underwent surgery for the CRLMs, were enrolled. Four radiologists reviewed the anonymized data, which were then randomly allocated into two groups (groups A and B), to be read by two independent readers.
The readers would define true absence of tumor as pathologic absence of tumor for resected lesions and no in situ recurrence within one year after surgery for lesions left unresected at each three-month follow-up contrast-enhanced CT. Positive predictive values (PPV) for absence of tumor and for residual tumor on contrast-enhanced CT and EOB MR images were compared by using a generalized estimating equation.
The results showed that among the 393 CRLMs, the PPV for absence of tumor on EOB MR images was significantly higher than that on contrast-enhanced CT scans, and the PPV for residual tumor on CT scans was higher than that on EOB MR images, but this was not statistically significant.
The researchers concluded that EOB MR imaging was superior to contrast-enhanced CT imaging for assessment of disappearing CRLMs after chemotherapy.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Large Medicare Study Shows Black Men Less Likely to Receive PET and MRI for Prostate Cancer Imaging
August 3rd 2025An analysis of over 749,000 Medicare beneficiaries diagnosed with prostate cancer over a five-year period found that Black men were 13 percent less likely to receive PET imaging and 16 percent less likely to receive MRI in comparison to White men.
The Reading Room Podcast: Current and Emerging Insights on Abbreviated Breast MRI, Part 3
August 3rd 2025In the last of a three-part podcast episode, Stamatia Destounis, MD, Emily Conant, MD and Habib Rahbar, MD, share additional insights on practical considerations and potential challenges in integrating abbreviated breast MRI into clinical practice, and offer their thoughts on future research directions.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 3rd 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.
The Reading Room Podcast: A Closer Look at Remote MRI Safety, Part 3
August 3rd 2025In the third of a three-part podcast episode, Emanuel Kanal, M.D. and Tobias Gilk, MRSO, MRSE, discuss strategies for maintaining the integrity of time-out procedures and communication with remote MRI scanning.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
August 3rd 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.